跳至主要内容
临床试验/NCT03130582
NCT03130582已完成不适用

2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria

Yang Jun0 个研究点目标入组 88 人开始时间: 2005年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
88
主要终点
relapse

研究概览

简要总结

patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48 hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs. Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4×109/L with blood cell The harvested cells reached at least 2*108/kg for mononuclear cells and/or 2*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen in liquid nitrogen.Auto-PBSCT

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 60 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • relapsed/refractory lymphoma ,siut APBSCT

排除标准

  • bone marrow without involvement by lymphoma cells

研究组 & 干预措施

Disease status at mobilization PR

干预措施: high-dose etoposide (Drug)

Disease status at mobilization PD

干预措施: high-dose etoposide (Drug)

结局指标

主要结局

relapse

时间窗: 10 years

relapse

death

时间窗: 10 years

death

CR

时间窗: 10 years

Complete response

次要结局

未报告次要终点

研究者

发起方
Yang Jun
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Yang Jun

Principal Investigator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

相似试验